Research ArticleCancer

Integration of Hedgehog and mutant FLT3 signaling in myeloid leukemia

See allHide authors and affiliations

Science Translational Medicine  10 Jun 2015:
Vol. 7, Issue 291, pp. 291ra96
DOI: 10.1126/scitranslmed.aaa5731

This article has a correction. Please see:

Abstract

FMS-like tyrosine kinase 3 (FLT3) internal tandem duplication (ITD) mutations resulting in constitutive kinase activity are common in acute myeloid leukemia (AML) and carry a poor prognosis. Several agents targeting FLT3 have been developed, but their limited clinical activity suggests that the inhibition of other factors contributing to the malignant phenotype is required. We examined gene expression data sets as well as primary specimens and found that the expression of GLI2, a major effector of the Hedgehog (Hh) signaling pathway, was increased in FLT3-ITD compared to wild-type FLT3 AML. To examine the functional role of the Hh pathway, we studied mice in which Flt3-ITD expression results in an indolent myeloproliferative state and found that constitutive Hh signaling accelerated the development of AML by enhancing signal transducer and activator of transcription 5 (STAT5) signaling and the proliferation of bone marrow myeloid progenitors. Furthermore, combined FLT3 and Hh pathway inhibition limited leukemic growth in vitro and in vivo, and this approach may serve as a therapeutic strategy for FLT3-ITD AML.

INTRODUCTION

Mutations involving internal tandem duplications (ITD) of the FMS-like tyrosine kinase 3 (FLT3) juxtamembrane domain result in constitutive receptor tyrosine kinase (RTK) activity and are clinically associated with high disease burden at diagnosis, short remissions, and poor overall survival (1). FLT3-ITD mutations are typically found in acute myeloid leukemia (AML) along with a wide range of other genetic alterations, suggesting that additional cellular events are required for its full pathogenic effects (2, 3). In transgenic mouse models, the expression of Flt3-ITD as a single genetic lesion within the hematopoietic system causes a gradual expansion of myeloid cells resembling an indolent myeloproliferative neoplasm (MPN), but other genetic events are required for the full development of AML (411). Unfortunately, most of these cooperating genetic lesions cannot be therapeutically targeted, and therefore, the identification of other cellular pathways activated in FLT3-mutant cells may lead to improved treatment strategies.

The highly conserved Hedgehog (Hh) signaling pathway is required for normal embryonic development and is active in a wide variety of cancers by promoting tumor cell proliferation and survival (12). Signaling is initiated by binding of one of the three mammalian Hh ligands to the cell surface receptor Patched (PTCH1), a 12-pass transmembrane receptor that inhibits the 7-pass transmembrane protein Smoothened (SMO). After Hh ligand binding, SMO is derepressed and ultimately modulates the three GLI transcriptional regulators and expression of target genes such as CyclinD1 and N-Myc to regulate cell proliferation, survival, and differentiation. Although the pathway is silenced in most postnatal tissues, it is reactivated in several solid tumors, and the clinical activity of the SMO antagonist vismodegib in advanced basal cell carcinoma (aBCC) has confirmed that Hh signaling represents a bona fide anticancer target (13).

Aberrant Hh signaling has also been implicated in hematologic malignancies of lymphoid origin, including multiple myeloma and acute lymphoblastic leukemia (14, 15), but its role in myeloid malignancies is less clear. Multiple studies have found that the modulation of Smo activity affects tumor growth in mouse models of BCR-ABL–driven chronic myeloid leukemia (CML) but does not affect the development or propagation of AML induced by the MLL-AF9 fusion gene (1618). Because crosstalk between Hh and RTK signaling occurs in several systems (1921) and because Hh pathway activation accentuates the oncogenic effects of the BCR-ABL tyrosine kinase, we examined the impact of Hh signaling in FLT3-ITD AML. We found that the expression of GLI2 was increased in FLT3-ITD compared to wild-type FLT3 AML cases. Constitutive activation of Hh signaling in the hematopoietic system of mice expressing Flt3-ITD enhanced signal transducer and activator of transcription 5 (STAT5) activity, myeloid progenitor expansion, and the development of AML. Furthermore, combined blockade of Hh and FLT3 signaling inhibited leukemic growth in vitro and in vivo. Therefore, aberrant Hh pathway activation promotes the development of AML, and combinatorial therapy with FLT3 and Hh pathway inhibitors may improve the treatment of FLT3-mutated disease.

RESULTS

The expression of the Hh pathway effector GLI2 is increased in FLT3-ITD AML

To identify cellular pathways active in FLT3-mutant AML, we initially examined several gene expression profiling (GEP) data sets. Early GEP studies distinguished subgroups of AML on the basis of hierarchical clustering, and a landmark report identified two subgroups enriched in FLT3-ITD mutations (22). Within one of these FLT3-ITD subgroups (cluster 2), the most significantly expressed gene by significance analysis of microarrays was GLI2, a critical effector of Hh signaling required for responsiveness to Hh ligand during embryonic development (2325). We examined three additional AML data sets and similarly found that GLI2 expression was higher in FLT3-ITD compared to wild-type FLT3 AML (Fig. 1A) (3, 26, 27). Moreover, within The Cancer Genome Atlas (TCGA), the expression of GLI2 in FLT3-ITD cases correlated with the major Hh target gene GLI1, indicative of active Hh signaling (fig. S1A). GLI2 and its target gene BCL2 were also overexpressed in primary FLT3-ITD clinical specimens compared to both wild-type FLT3 AML and normal CD34+ hematopoietic stem and progenitor cells (HSPCs) (Fig. 1B), whereas GLI1 was highly expressed in both FLT3-ITD and wild-type AML (fig. S1B). We also examined FLT3-ITD specimens within TCGA’s data set and found that higher GLI2 (P = 0.046), but not GLI1 expression, was associated with a shorter median overall survival (fig. S1, C and D). Therefore, the inferior survival of FLT3-ITD AML cases overexpressing GLI2 suggests that the Hh pathway contributes to the pathogenic impact of this common genetic abnormality.

Fig. 1. GLI2 expression is increased in human FLT3-ITD AML.

(A) GLI2 expression in human AML data sets (probe GLI2 − 228537_at) or TCGA. (B) Relative GLI2 and BCL2 expression in primary AML samples compared to normal CD34+ HSPCs [n = 5 for HSPCs, wild-type (WT) FLT3, and FLT3-ITD specimens]. Data represent mean ± SD. n.d., not detected.

Hh pathway activation drives the progression of indolent myeloproliferative disease

To examine the functional impact of Hh signaling in FLT3-ITD AML, we crossed transgenic Flt3-ITD mice in which an 18–base pair ITD mutation has been knocked into the Flt3 juxtamembrane domain with mice expressing the constitutively active SMO mutant, SmoM2, fused to yellow fluorescent protein (YFP) from the Rosa26 locus (28, 29). Conditional expression of both FLT3-ITD and SmoM2 within the hematopoietic system was induced by Mx1-Cre and poly(I:C) (polyinosinic-polycytidylic acid) treatment and confirmed by polymerase chain reaction (PCR) and the detection of YFP in peripheral blood cells (fig. S2, A to C) (30). Furthermore, we detected the expression of Gli2 in Mx1-Cre;SmoM2 (SmoM2), Mx1-Cre;Flt3-ITD (Flt3/ITD), and Mx1-Cre;SmoM2;Flt3-ITD (Flt3/ITD-SmoM2) mice, as well as Gli1, a major Hh pathway target, in SmoM2 and Flt3/ITD-SmoM2 mice (fig. S2D). In contrast, Gli1 and Gli2 were not expressed in animals lacking Mx1-cre. The expression of Gli2 in the absence of Gli1 by Flt3/ITD bone marrow cells suggests that GLI2 does not primarily drive pathway activation but allows cells to be responsive to Hh ligands, similar to what happens in the developing neural tube and genital tubercle (31, 32). We also found that recombinant Sonic Hh (SHH) ligand could induce Gli1 expression in bone marrow cells of Flt3/ITD but not wild-type mice (fig. S2E).

FLT3-ITD mutations primarily occur in de novo AML and are associated with rapidly proliferating disease, but similar to previous findings, heterozygous Flt3-ITD expression in mice resulted in gradually increasing peripheral WBC counts resembling a chronic MPN, with a median life span of 40 weeks; the expression of SmoM2 alone did not alter peripheral blood counts or survival compared to wild-type controls (Fig. 2A) (28). In contrast, the median survival of Flt3/ITD-SmoM2 mice was significantly shorter than Flt3/ITD animals at 12 weeks (P = 0.0001) and was associated with elevated peripheral WBC counts and the generation of a new population of Mac1+Gr1int leukemic blasts about 3 weeks after poly(I:C) administration (Fig. 2, B to D). Within the bone marrow, Flt3/ITD-SmoM2 animals demonstrated significantly increased cellularity compared to Flt3/ITD mice because of the accumulation of an abnormal population of immature cKit+Gr1int myeloid cells (Fig. 2E; P = 0.03). These cells also infiltrated the spleen, resulting in splenomegaly, as well as nonhematopoietic organs such as the liver and lungs (Fig. 2, F and G, fig. S2F, and table S1). Infiltration within the bone marrow also resulted in the reduction of red blood cell and platelet counts (Fig. 2G and fig. S2G). The accelerated death of Flt3/ITD-SmoM2 mice along with increased numbers of myeloid blasts in the bone marrow and spleen, infiltration of myeloid cells into nonhematopoietic organs, and increased number of myeloid cells in the peripheral blood indicate that constitutively active Hh signaling induces disease progression in Flt3/ITD animals to an MPN-like myeloid leukemia based on established criteria (33).

Fig. 2. Flt3/ITD-SmoM2 mice develop rapidly fatal AML.

(A) Kaplan-Meier survival curve of transgenic animals after poly(I:C) induction. Statistical significance determined by log-rank (Mantel-Cox) test comparing Flt3/ITD and Flt3/ITD-SmoM2 animals. (B) White blood cell (WBC) counts at 3 months after the completion of poly(I:C) treatment. Data represent mean ± SD. (C) Wright-Giemsa staining of peripheral blood smears. (D) Fluorescence-activated cell sorting (FACS) analysis of peripheral blood cells. Bar graph represents percentage of Mac1+Gr1+ cells (n = 5 to 7 per genotype). Data represent mean ± SD. (E) FACS analysis of bone marrow cells. Bar graph depicts bone marrow cellularity and percentage of Gr1+cKit+ cells (n = 3 to 7 per genotype). Data represent mean ± SD. (F) Spleen weights and representative spleen sizes. Data represent mean ± SD. (G) Hematoxylin and eosin staining of bone marrow and spleen sections. RP, red pulp; WP, white pulp.

Myeloid progenitor compartments are expanded in Flt3/ITD-SmoM2 mice

Compared to wild-type mice, Flt3/ITD mice display increased numbers of lineage-negative (Lin) multipotent bone marrow cKit+Sca1+ (KSL) HSPCs as well as committed myeloid progenitors (28). In Flt3/ITD-SmoM2 mice, we found that Lin cells were increased compared to Flt3/ITD mice, but the frequency and total number of KSL cells, long-term hematopoietic stem cells (KSL CD150+CD48CD34), short-term hematopoietic stem cells (KSL CD34+Flk2), and multipotent progenitors (KSL CD34+Flk2+) did not change (Fig. 3, A and B, and fig. S3A). In contrast, cKit+Sca1Lin myeloid progenitors were increased by twofold in Flt3/ITD-SmoM2 mice, primarily due to the expansion of granulocyte/monocyte progenitors (GMPs; cKit+Sca1LinCD34+Flk2+) but not of common myeloid (CMP; cKit+Sca1LinCD34+Flk2) or of megakaryocyte/erythrocyte progenitors (MEPs; cKit+Sca1LinCD34Flk2). Therefore, peripheral blood leukocytosis and the increased frequency of leukemic blasts in Flt3/ITD-SmoM2 mice arise from the relative expansion of the GMP compartment.

Fig. 3. Myeloid progenitors are expanded and more proliferative in Flt3/ITD-SmoM2 mice.

(A) Representative FACS plots depicting relative percentages of stem and progenitor KSL (LinSca1+cKit+), myeloid progenitor (LinSca1cKit+), GMP (LinSca1cKit+CD34+CD16/32+), CMP (LinSca1cKit+CD34+CD16/32), and MEP (LinSca1cKit+CD34CD16/32) cells in bone marrow of transgenic animals. (B) Total number of cells of each specific type per femur (n = 3 to 7 animals per genotype). Data represent mean ± SD. n.s., not significant. (C) Representative FACS plots of cells with BrdU incorporation in KSL, CMP, GMP, and MEP compartments. (D) Frequency of BrdU-positive cells from each population (n = 5). Data represent mean ± SD.

The proliferation of myeloid progenitors is increased in Flt3/ITD-SmoM2 mice

Both increased FLT3 signaling and Hh pathway activity enhance the proliferation and survival of myeloid leukemia cells (16, 34). To determine the impact of Hh signaling on FLT3-ITD cells, we studied the proliferation of bone marrow cells by quantifying bromodeoxyuridine (BrdU) incorporation. Compared to Flt3/ITD mice, BrdU incorporation in bone marrow cells of Flt3/ITD-SmoM2 mice was similar for most primitive HSPC populations (fig. S3B), but it was increased by greater than twofold in GMPs, which were markedly expanded in the bone marrow of Flt3/ITD-SmoM2 mice (Fig. 3, C and D). BrdU incorporation was also increased in KSL cells and MEPs, although total numbers of these cells were not increased in Flt3/ITD-SmoM2 mice. Therefore, Hh pathway activity increases the number of GMPs by increasing their proliferative potential.

Hh signaling affects malignant hematopoiesis in a cell-intrinsic manner

In some cancers, aberrant Hh pathway activation is mediated by autocrine signaling, in which tumor cells both produce and respond to Hh ligand (14, 35, 36). In other diseases, paracrine signaling has also been described, such that tumor cells secrete Hh ligands and induce pathway activation in nonmalignant stromal cells but not tumor cells (37). We initially studied the role of bone marrow stromal cells in the propagation of leukemia from Flt3/ITD-SmoM2 mice by transplanting AML cells into wild-type recipients. However, we could not detect leukemic engraftment 8 weeks after transplantation despite cell doses of up to 10 million cells, similar to previous studies with Flt3-ITD mice (38). Because the Mx1 promoter can be activated by poly(I:C) in multiple cell types, including bone marrow stromal cells (30), we next examined whether the generation of AML by SmoM2 requires cell-intrinsic or cell-extrinsic Hh signaling. We transplanted bone marrow from unexcised CD45.2 Flt3/ITD-SmoM2 mice into wild-type congenic CD45.1 recipient animals (fig. S4A). After the generation of stable donor blood chimerism, recipient mice were treated with poly(I:C) and developed AML with similar tumor cell phenotype and survival as Flt3/ITD-SmoM2 mice (fig. S4, B and C). We also detected YFP expression by flow cytometry within CD45.2+ bone marrow hematopoietic cells but not CD45 cells, indicating that stromal cells did not express SmoM2 (fig. S4D). Therefore, Hh signaling enhances AML progression in Flt3/ITD animals in a cell-autonomous manner.

Constitutive Smo activity enhances STAT5 signaling in Flt3-ITD cells

To determine the mechanisms by which Hh pathway activation affects FLT3-ITD signaling, we initially compared the gene expression profiles of isolated KSL and GMP cells from wild-type, Flt3/ITD, and Flt3/ITD-SmoM2 mice. We used Gene Set Enrichment Analysis (GSEA) and focused on biological pathways frequently activated during oncogenesis, such as proliferation, survival, and self-renewal (39). Among the top GSEA sets, we identified a gene signature consistent with increased STAT5 signaling in Flt3/ITD compared to wild-type animals, as expected from the known role of STAT5 as a major downstream target of FLT3-ITD required for the survival and proliferation of myeloid leukemia cells (Wierenga_STAT5_targets_group2) (fig. S5A). We also used the analysis of functional annotation (AFA) method to further confirm the enrichment of STAT5 signaling functional gene sets (40, 41). Compared to Flt3/ITD mice, the STAT5 signature was further augmented in cells from Flt3/ITD-SmoM2 mice (Fig. 4A). To confirm these findings, we quantified the expression of STAT5 target genes and found that several were elevated in GMPs isolated from the bone marrow of Flt3/ITD-SmoM2 mice compared to Flt3/ITD mice (Fig. 4B). STAT5 also enhances cell survival, and we found that an antiapoptotic genetic signature was enriched in Flt3/ITD-SmoM2 compared to Flt3/ITD mice (Anti_apoptosis) (fig. S5B).

Fig. 4. STAT5 signaling is enhanced in Flt3/ITD-SmoM2 mice.

(A) GSEA analysis comparing Flt3/ITD and Flt3/ITD-SmoM2 mice. NES, normalized enrichment score; FDR, false discovery rate. (B) Quantitative reverse transcription PCR (qRT-PCR) analysis of STAT5 target genes in sorted GMP cells (n = 3). Data represent mean ± SD.

The extent of STAT5 activation corresponds to disease acuity, as evidenced by homozygous Flt3ITD/ITD mice, which experienced a shorter survival than heterozygous Flt3-ITD mice (42, 43). In multiple studies, the transformation of MPN to AML is associated with increased STAT5 signaling driven by loss of the wild-type Flt3 allele to generate hemizygous Flt3ITD/− AML (68). We examined both whole bone marrow cells and FACS-isolated GMPs and did not find loss of heterozygosity; both wild-type and ITD mutant Flt3 genes were detected in Flt3/ITD-SmoM2 animals (fig. S5C). Therefore, Hh pathway activation in Flt3/ITD-SmoM2 mice promotes increased STAT5 activity and myeloid cell expansion.

Combined FLT3 and Hh pathway inhibition limits AML growth and proliferation in vitro

FLT3-ITD mutations carry a relatively poor prognosis in adult AML (1), and several small-molecule FLT3 tyrosine kinase inhibitors have undergone clinical testing (4447). Many of these agents can eliminate leukemic blasts in the peripheral blood, but the clinical responses are transient because tumor cells persist within the bone marrow (48). Seeing that Hh pathway activation enhanced the proliferative effects of FLT3-ITD, we examined whether pathway inhibition could augment the activity of FLT3 antagonists. The MV4-11 and Molm-14 human leukemia cell lines harbor the FLT3-ITD mutation (49), and we found that both expressed Hh signaling pathway components as well as Indian Hh ligand by RT-PCR (fig. S6A). We treated cells with the tyrosine kinase inhibitor sorafenib, which has clinical activity against FLT3-ITD AML (50), and the SMO antagonist IPI-926 to block Hh signaling (51). IPI-926 decreased GLI1 and GLI2 gene expression (fig. S6B) and modestly affected the growth of either cell line as a single agent (Fig. 5A and fig. S6C). However, the antiproliferative effects of sorafenib against MV4-11 and Molm-14 cells were significantly enhanced by IPI-926 (Fig. 5A and fig. S6C; P = 0.015 and P = 0.006) or knockdown of GLI2 by small interfering RNA (siRNA) (fig. S6D). These effects were specific for SMO inhibition, because both a second SMO inhibitor, LDE225, and siRNA against SMO had similar effects to IPI-926 (fig. S6, E and F). Moreover, further activation of Hh signaling in Molm-14 and MV4-11 cells with recombinant SHH ligand limited the effects of sorafenib (Fig. 5B and fig. S6G). Finally, we also found that this combination was active in clinical FLT3-ITD AML bone marrow specimens (Fig. 5C).

Fig. 5. IPI-926 and sorafenib inhibit leukemic cell growth in vitro.

(A) Viable cell counts of MV4-11 cells treated with IPI-926 and sorafenib for 3 days (n = 4). Data represent mean ± SD. (B) Viable cell counts of MV4-11 cell lines treated with recombinant SHH ligand and sorafenib for 3 days (n = 3). Data represent mean ± SD. (C) Viable cell counts of clinical FLT3-ITD AML specimens treated with IPI-926 and sorafenib for 3 days (n = 4 individual patients). Data represent mean ± SD. (D) Cell cycle distribution of MV4-11 cells treated with IPI-926 and sorafenib after 3 days (n = 3). Data represent mean ± SD. (E) Relative colony formation of MV4-11 cells in methylcellulose after treatment with IPI-926 and sorafenib for 3 days compared to vehicle control (n = 4). Data represent mean ± SD. (F) Western blot of pSTAT5, total STAT5, and tubulin from MV4-11 cells treated for 3 days. (G) Relative ratio of pSTAT5 to total STAT5 (n = 4). Data represent mean ± SD. (H) Relative levels of total STAT5 normalized to tubulin (n = 4). Data represent mean ± SD.

Leukemic progression within Flt3/ITD-SmoM2 mice is associated with the increased proliferation of GMPs (Figs. 3C and 5D); therefore, we examined the combined effects of sorafenib and IPI-926 on cell cycle progression and the survival of MV4-11 cells. Sorafenib induced an increase in G1 and G2-M cell cycle arrest compared to vehicle-treated cells, and the addition of IPI-926 further enhanced this effect (Fig. 5D; P = 0.024 and P = 0.034). Furthermore, this combination inhibited in vitro clonogenic leukemia growth more effectively than did either sorafenib or IPI-926 alone (Fig. 5E and fig. S6H). At the concentrations used, sorafenib induced a modest amount of apoptosis measured by Annexin V binding, but this effect was not significantly increased with the addition of IPI-926 or in wild-type FLT3 HL60 cells that lack GLI2 expression (fig. S6, I to K). Therefore, dual FLT3 and SMO inhibition primarily affects AML proliferation.

Because we found that the enhanced proliferation of GMPs in Flt3/ITD-SmoM2 mice is associated with increased STAT5 activity (Fig. 4A), we studied the effects of sorafenib and IPI-926 on STAT5 activity in MV4-11 cells. Sorafenib alone decreased the phosphorylation of STAT5 (pSTAT5), similar to previous reports (52), and it inhibited GLI1 and GLI2 expression (Fig. 5, F and G, and fig. S7A). IPI-926 alone also decreased the ratio of pSTAT5 to total STAT5 as well as decreased the overall expression of total STAT5 (Fig. 5, G and H). Treatment with the combination of sorafenib and IPI-926 further decreased overall pSTAT5 compared to either drug alone because of both lower expression of total STAT5 and a decreased proportion of STAT5 that was phosphorylated (Fig. 5F). SHH increased pSTAT5 and limited the effects of sorafenib but did not affect phosphorylated AKT (pAKT) or phosphorylated extracellular signal–regulated kinase (pERK), which can also be increased by FLT3 signaling (fig. S7B). To further demonstrate that the effects of combined treatment with sorafenib and IPI-926 were primarily mediated by STAT5, we studied BaF3 cells engineered to express FLT3/ITD (53). In these cells, interleukin-3 (IL-3) can rescue the effects of FLT3 inhibitors through the induction of STAT5 activation, and we found that it also decreased the effects of sorafenib and IPI-926 on both pSTAT5 and cell growth (fig. S7, C and D). Therefore, the inhibition of the Hh signaling pathway specifically enhances the antileukemic effects of FLT3 tyrosine kinase inhibition associated with the inhibition of STAT5.

Sorafenib and IPI-926 cooperate to inhibit leukemic cell growth in vivo

Given the impact of sorafenib and IPI-926 on AML cell lines in vitro, we examined this combination in vivo against Flt3/ITD-SmoM2–derived AML. Wild-type recipient mice were engrafted with bone marrow from Flt3/ITD-SmoM2 mice, treated with poly(I:C), and, after the development of AML, treated with sorafenib and/or IPI-926 daily for 16 days. Although mutated SmoM2 is relatively resistant to the naturally occurring Smo antagonist cyclopamine, IPI-926 inhibits SmoM2 in vitro and reduced the expression of the Hh target genes Gli1, Gli2, and Ptch1 by bone marrow cells in SmoM2 mice after drug treatment (fig. S8). The combination of sorafenib and IPI-926 reduced splenomegaly compared to either drug alone (Fig. 6A). Furthermore, this combination produced a significant reduction in the percentage of Mac1+Gr1+ leukemic cells in the peripheral blood and Gr1+cKit+ cells in the bone marrow (Fig. 6B; P = 0.049 and P = 0.045). Both sorafenib and IPI-926 treatment as single agents increased survival compared to vehicle-treated controls, but the combination further extended survival, with a proportion of the mice failing to succumb to disease despite no further treatment beyond the initial 16-day period (Fig. 6C). Similar to our in vitro studies, treatment with IPI-926 and sorafenib decreased both total STAT5 and active pSTAT5 compared to treatment with sorafenib alone (Fig. 6, D and E).

Fig. 6. Combined IPI-926 and sorafenib treatment improves survival.

(A) Representative spleen sizes of animals after 16 days of drug treatment. (B) Frequency of abnormal Gr1+Mac1+ and cKit+Gr1+ cells in the peripheral blood and bone marrow, respectively, of animals treated with drugs for 16 days (n = 3 per group). Data represented as mean ± SD. (C) Kaplan-Meier survival curve of animals treated with IPI-926 and sorafenib (n = 3 to 5 per group). Statistical significance determined by log-rank (Mantel-Cox) test. (D) pSTAT5 and total STAT5 in bone marrow cells harvested after 24 hours of drug treatment. (E) Ratio of pSTAT5 to total STAT5, normalized to vehicle-treated cells (n = 3). Data represent mean ± SD.

DISCUSSION

Most newly diagnosed cases of FLT3-mutated AML present with rapidly proliferating disease, but Flt3-ITD expression in mice causes an MPN marked by the gradual elevation of peripheral WBC counts (28). We found that constitutively active SMO cooperates with aberrant FLT3 activity to generate AML, and combined treatment with FLT3 and Hh pathway inhibitors decreased leukemic growth in vitro and in vivo. We also identified increased GLI2 expression in FLT3-ITD clinical AML specimens, suggesting that these findings are clinically relevant. Mutations in Hh pathway components are rare in AML (3), but a recent report also demonstrated that increased wild-type spleen tyrosine kinase (SYK) activity can induce the transformation of Flt3-mutant AML (54). Therefore, mutated FLT3 may remain dependent on the activity of nonmutated cellular pathways for AML pathogenesis.

There are limitations to our study. SMO antagonists are clinically effective in aBCC in which Hh signaling is aberrantly activated by PTCH1 and SMO mutations. We used an Smo mutant to constitutively activate the pathway in vivo and found that SMO inhibitors were active when combined with FLT3 inhibition. However, alterations in PTCH1 or SMO are uncommon in most human cancers, including AML (3, 12), and it is possible that SMO inhibition will not be effective in the absence of these pathway-activating mutations. We also used sorafenib to study FLT3 inhibition, but several new FLT3 antagonists, such as quizartinib, are in clinical development (55). Therefore, it is also possible that Hh pathway antagonists will not enhance the activity of these agents because our observed effects were due to the inhibition of other kinases that can be targeted by sorafenib (56), and further studies with next-generation FLT3 and Hh pathway inhibitors are needed.

The Hh pathway interacts with several other cellular pathways in a wide range of tumor types (12), and we have identified a functionally relevant interaction between Hh and FLT3 signaling in AML. In several solid tumors, mutant RAS or the activation of RTKs, such as the epidermal growth factor receptor, results in aberrant RAS/RAF/MAPK kinase (MEK) and phosphatidylinositol 3-kinase (PI3K)/AKT signaling and the direct activation of GLI1 (21, 5759). Although FLT3-ITD is a constitutively active RTK, Gli1 expression was low in bone marrow cells from Flt3/ITD mice at baseline but induced by SHH ligand. In contrast, Gli1 levels did not change in wild-type cells, and the differential expression of Gli2 may have restricted Hh ligand responsiveness to Flt3/ITD cells. Therefore, Flt3-ITD may directly or indirectly induce Gli2, which in turn allows canonical signaling by Hh ligand or directly affects AML cell proliferation. Both wild-type and mutant FLT3 cells expressed more GLI1 than did normal HSPCs, suggesting that GLI1 activity may be broadly required in AML. Furthermore, because GLI2 was primarily increased in FLT3-ITD cases and RAS mutations are also common in AML (3), GLI1 activation may broadly occur in AML through Hh ligand–mediated canonical signaling or direct activation by mutant RAS. Sorafenib alone decreased the growth of FLT3-ITD cells as well as GLI1 and GLI2 expression; therefore, it is also possible that Hh signaling can be at least partially inhibited by FLT3 inhibition alone.

Despite the biologic diversity of mutations that enhance leukemic progression of Flt3/ITD mice, a common mechanism for leukemic progression is the loss of the wild-type Flt3 allele by acquired segmental uniparental disomy, resulting in increased tyrosine kinase activity and activation of the major downstream target STAT5 (42, 43). Although loss of heterozygosity of the Flt3 allele did not occur in the Flt3/ITD-SmoM2 mice, we found that STAT5 activity was increased. STAT5 is one of the main downstream targets of aberrant FLT3-ITD signaling, and increased STAT5 activity is associated with shortened overall survival in patients with FLT3-mutated AML (60, 61). The treatment of both human and mouse AML cells with sorafenib and IPI-926 decreased active pSTAT5 by inhibiting both its phosphorylation by FLT3-ITD and total STAT5 expression in response to SMO inhibition. The modulation of STAT5 activity by the Hh signaling pathway has also been described in the development of the mammary gland and brain (6264), and chromatin immunoprecipitation studies have identified the STAT5a gene within GLI1-bound regions in both medulloblastoma and normal granule neuron precursor cells (64). Because STAT5 signaling is important in the pathogenesis of CML as well as other forms of leukemia (65, 66), it is possible that this interaction may also explain the impact of the Hh pathway on BCR-ABL activity (16, 17).

FLT3 mutations are the most common genetic alterations identified in AML, and several inhibitors of FLT3 kinase activity have undergone clinical testing. Although these inhibitors can eliminate leukemic blasts in the peripheral blood, bone marrow responses are much less frequent (48). The failure of these agents to produce complete remissions may be due in part to the lack of in vivo potency and complete and sustained FLT3 inhibition (67). We found that IPI-926 enhanced the effects of sorafenib on the proliferation and survival of mutant FLT3 AML cells both in vitro and in vivo. Other recent data demonstrated that inhibition of GLI1 and SMO can enhance the activity of the conventional cytotoxic agent cytarabine in AML, suggesting a broad role for the Hh pathway in therapeutic resistance (68). Therefore, SMO antagonists may improve the clinical utility of FLT3 inhibitors for the treatment of AML through multiple mechanisms.

MATERIALS AND METHODS

Study design

The overall study objective was to determine the role of the Hh signaling pathway in FLT3-ITD AML by analyzing the development of leukemia in a transgenic mouse model with or without the constitutive activation of SMO. Sample size calculations were not performed for initial studies, because these were undertaken to identify an interaction between the FLT3 and Hh pathways. Subsequent studies were stopped when double transgenic mice became symptomatic, and littermate controls were analyzed at the same time points. Controlled laboratory experiments also included the analysis of AML cell lines treated with FLT3 and Hh antagonists. Studies were carried out at least in triplicate, and no data were excluded in the final analysis. No blinding occurred throughout the study.

Clinical specimens, cell lines, and drug treatment

Bone marrow specimens were obtained from patients with newly diagnosed AML or normal donors granting informed consent as approved by the Johns Hopkins Medical Institutes Institutional Review Board. CD34+ cells were isolated using magnetic microbeads (Miltenyi). Clinical specimens, human FLT3-ITD MV4-11 and Molm-14, and wild-type FLT3 HL60 AML cell lines were cultured in RPMI medium supplemented with 10% fetal bovine serum, 0.5% l-glutamine, and 0.5% penicillin/streptomycin at 37 °C. Similar culture conditions were used for the BaF3/ITD cell line (53). Treatments consisted of IPI-926 (2.5 μM; Infinity Pharmaceuticals), SHH ligand (10 ng/ml; StemRD), LDE225 (5 μM; LC Laboratories), IL-3 (10 ng/ml; PeproTech), and/or sorafenib (LC Laboratories) for 3 days. Sorafenib was used at concentrations of 1 nM for MV4-11 cells and 3 nM for clinical specimens, Molm-14, and BaF3/ITD cells. Viable cells were quantified with a hemocytometer and trypan blue dye exclusion or, in some cases, incubated (500 cells/ml) in methylcellulose at 37 °C for 7 days followed by the quantification of tumor cell colonies (>40 cells per colony) using an inverted microscope (Nikon). Cell viability was also assessed using the Cell Proliferation I Kit (Roche) and an iMark Microplate Reader (Bio-Rad). Cell cycle analysis was carried out by incubating cells in phosphate-buffered saline containing 0.6% NP-40 (Sigma), 40 μg of propidium iodide, and ribonuclease (2 μg/ml) (Roche) followed by flow cytometry analysis with a FACSCalibur (BD Biosciences).

Mice

All animal procedures were approved by the Institutional Animal Care and Use Committee. Flt3/ITD mice harboring an ITD mutation knocked into the endogenous Flt3 locus have been previously described (28). SmoM2 and Mx1-Cre mice were obtained from the Jackson Laboratory. Genotyping was determined by PCR (table S2), and mice harboring alleles heterozygous for SmoM2, Flt3-ITD, and/or Mx1-Cre were obtained. Littermates with single copies of the SmoM2 or Flt3-ITD alleles were used as controls, whereas wild-type controls carried the Mx1-Cre allele alone. After weaning and genotyping, mice were treated with five doses of poly(I:C) (300 μg; Sigma) intraperitoneally every other day, and successful transgene excision was confirmed 4 weeks after the last poly(I:C) injection by PCR of peripheral blood DNA with primers for the loxP sites (table S2). Peripheral blood mononuclear cells were also analyzed for YFP expression by flow cytometry (FACSCalibur, BD Biosciences). The development of AML was assessed by the presence of Mac1+Gr1+ cells in the peripheral blood and Gr1+cKit+ cells in the bone marrow by flow cytometry. Mice were sacrificed after the developed lethargy, hunching, and weight loss, and bone marrow was analyzed by flow cytometry. Formalin-fixed tissues were stained with hematoxylin and eosin and blood smears with Wright-Giemsa stain. Complete peripheral blood counts were quantified using a Hemavet 950 analyzer (Drew Scientific).

In vivo drug treatment

IPI-926 was formulated in a 5% β-cyclodextrin (Sigma) solution with deionized H2O, and mice were given IPI-926 (20 mg/kg) or the same volume of 5% β-cyclodextrin solution once a day for 16 days by oral gavage. Sorafenib was formulated in 100% dimethyl sulfoxide (Sigma), and mice were given sorafenib or vehicle (10 mg/kg) once a day for 16 days by oral gavage. The vehicle solution for sorafenib consisted of 30% (w/v) Cremophor EL, 30% (w/v) PEG-400 (polyethylene glycol, molecular weight 400), 10% ethanol, and 10% glucose (all Sigma-Aldrich). Some mice were also given the combined treatment of sorafenib and IPI-926. The vehicle-treated group received both 5% β-cyclodextrin solution and the vehicle solution for sorafenib.

Antibodies and FACS

Monoclonal antibodies against Mac1, Gr1, B220, and CD3 (all from eBioscience) were used for peripheral blood analysis. Bone marrow lineage staining was carried out with biotinylated antibodies against Gr1, Ter119, B220, and CD3 (all from eBioscience). Bone marrow cells were also stained with antibodies against cKit, Sca1, CD16/32, CD34, FLT3, CD150, CD48, and IL-7R (all from eBioscience). Flow cytometry and BrdU staining were carried out as previously described (69). Apoptosis was determined by Annexin V binding (BD Biosciences). Flow cytometry was performed on FACSCalibur or LSRII flow cytometers (BD Biosciences) and analyzed with FlowJo software. Cell sorting was carried out on a FACSAria II (BD Biosciences).

Quantitative real-time PCR analysis

Total RNA was extracted with the RNeasy Plus Mini Kit (Qiagen) and reverse-transcribed with SuperScript III reverse transcriptase (Invitrogen). qRT-PCR was carried out with TaqMan and SYBR Green Master Mix (ABI) according to the manufacturer’s protocols (table S2).

Microarray and GSEA analysis

Analysis of published data sets (3, 26, 27) involved normalized gene expression data, as originally provided by the authors, downloaded from the National Center for Biotechnology Information Gene Expression Omnibus (GEO) database (GSE10358, GSE14468), the TCGA Research Network (AML) at http://cancergenome.nih.gov, or cBioPortal at http://www.cbioportal.org/public-portal (70, 71). Log2-transformed GLI2 and GLI1 gene expression was compared between FLT3-ITD and wild-type FLT3 tumors using t test. KSL and GMP cells were isolated by FACS from wild-type, Flt3/ITD, and Flt3/ITD-SmoM2 animals at about 3 months of age or when Flt3/ITD-SmoM2 animals were moribund. Total RNA was extracted and hybridized onto the Affymetrix Mouse Genome 430 2.0 array (Affymetrix) followed by microarray scanning with the Affymetrix GeneChip scanner and data analysis with the GeneChip Operating Software (Affymetrix). Gene expression data preprocessing and normalization were performed by the frozen robust multiarray analysis (fRMA) method (72). Gene set enrichment analysis was performed with JAVA-based GSEA software provided by the Broad Institute of the Massachusetts Institute of Technology (39). The AFA was performed as previously described (40, 41). Gene sets were obtained from Molecular Signatures Database (MSigDB, C2 collection). Antiapoptosis gene set was obtained from the Gene Ontology collection (GO:0006916). The curated gene set of STAT5 signature in CD34+ HSPCs was obtained from MSigDB and was previously published (73).

Western blot

Cell lysates were separated by SDS–polyacrylamide gel electrophoresis followed by Western blotting using rabbit anti-total STAT5 (#9396), pSTAT5-Y694 (#9351), total STAT3 (#12640), total AKT (#9272), pAKT (#9271), total ERK1/2 (#9102), and pERK (#9101), all from Cell Signaling, or tubulin (#21058; Abcam), followed by a horseradish peroxidase–conjugated goat anti-rabbit secondary antibody (#NA934V; Amersham). Film was developed using Amersham ECL Plus Western Blotting Detection Reagents (GE Healthcare). Images were obtained with the GS-900 calibrated densitometer and quantified with Image Lab software (Bio-Rad).

Small interfering RNA

MV4-11 and Molm-14 cell lines were transfected with ON-TARGETplus SMARTpool siRNAs targeting human SMO and GLI2 (Dharmacon), using an Amaxa Nucleofector (Lonza). Successful knockdown of the genes was determined by qRT-PCR 24 hours after transfection, after which cells were treated with sorafenib.

Statistics

Log-rank (Mantel-Cox) test P values for the Kaplan-Meier survival curves were generated using GraphPad Prism. All other P values were calculated with unpaired two-tailed Student’s t test, unless otherwise specified. All experiments were performed independently at least three times. Pearson’s R value for correlation and P value was generated in GraphPad Prism. P values <0.05 were considered statistically significant. Original data for patient samples and animal experiments are provided in table S3.

SUPPLEMENTARY MATERIALS

www.sciencetranslationalmedicine.org/cgi/content/full/7/291/291ra96/DC1

Fig. S1. GLI2 is expressed in FLT3-ITD AML clinical specimens.

Fig. S2. Flt3/ITD-SmoM2 transgenic mice express Hh pathway genes and develop clinically relevant AML.

Fig. S3. Specific bone marrow hematopoietic stem cell and myeloid progenitor compartments are maintained in Flt3/ITD-SmoM2 mice.

Fig. S4. Leukemia formation in Flt3/ITD-SmoM2 mice is cell-intrinsic.

Fig. S5. GSEA reveals increased STAT5 signaling in Flt3/ITD and antiapoptotic features in Flt3/ITD-SmoM2 mice.

Fig. S6. The combination of sorafenib and IPI-926 limits the growth of FLT3-ITD AML.

Fig. S7. Hh signaling affects FLT3-ITD at the level of STAT5.

Fig. S8. IPI-926 inhibits the expression of Hh target genes in Flt3/ITD-SmoM2 bone marrow cells.

Table S1. Leukemic organ infiltration.

Table S2. PCR primers.

Table S3. Original data (provided as a separate Excel file).

REFERENCES AND NOTES

  1. Acknowledgments: We thank all patients and donors who contributed peripheral blood and/or bone marrow specimens for these studies. Funding: This study was supported by research grants from the NIH (R01CA127574, R01CA174951, R01CA090668, R21CA155733, P30DK090868, P30CA006973, and UL1TR001079) to W.M., D.S., D.L.H., and L.M. Support was also provided by the Leukemia and Lymphoma Society, the Gabrielle’s Angel Foundation for Cancer Research, the Edward P. Evans Foundation, and the Petre Foundation. Author contributions: Y.L. and W.M. designed the studies, analyzed the data, and wrote the manuscript. Y.L., L.G., L.L., Q.W., H.M., E.C., D.L.H., S.F., C.D.P., and A.A.M. carried out the studies. K.M., D.N.W., and A.A.M. contributed to the design and performance of some of the studies. L.G. and L.M. carried out the bioinformatics studies. B.D.S. and M.L. provided the clinical specimens. L.G., B.D.S., A.A.M., and D.S. contributed to the study design and writing of the manuscript. Competing interests: K.M. is an employee of Infinity Pharmaceuticals. The other authors declare that they have no competing interests. Data and materials availability: Oligonucleotide microarray data have been deposited in the GEO under accession number GSE67134. IPI-926 was obtained from Infinity Pharmaceuticals through a materials transfer agreement with Johns Hopkins University.
View Abstract

Navigate This Article